RxDoctor Payments Data

Joshan Shajan, MD

General Practice · San Diego, CANPI 1790043040

Payments from drug & device makers

$11,224in general payments, 2019–2025

Across 597 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$687
  • Astellas Pharma US Inc$637
  • Amgen$599
  • Pfizer$560
  • GSK$539
  • plus $5K from 50 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$10,96098%
  • Education$2402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)191$3,676
AstraZeneca43$687
Astellas Pharma US Inc23$637
Amgen(2 entities)33$599
Pfizer31$560
GSK21$539
Merck22$401
Bayer11$309
Eisai Inc.26$260
Novartis14$257
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$256
Amarin Pharma, Inc.13$238
Kowa Pharmaceuticals America, Inc.16$232
Johnson & Johnson(2 entities)11$186
Teva Pharmaceuticals USA, Inc.9$177
Nestle Healthcare Nutrition Inc.10$172
Sunovion Pharmaceuticals Inc.9$152
Scilex Pharmaceuticals Inc.9$150
Boehringer Ingelheim8$141
Takeda Pharmaceuticals U.S.A., Inc.9$140
Exact Sciences4$118
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$116
Supernus Pharmaceuticals, Inc.5$113
Otsuka America Pharmaceutical, Inc.5$108
Organogenesis Inc.1$103
Lilly USA, LLC5$94
Genentech USA, Inc.5$91
Biohaven Pharmaceutical Holding Company Ltd.3$57
Sanofi Pasteur Inc.3$50
Ironwood Pharmaceuticals, Inc3$45
Jazz Pharmaceuticals Inc.2$45
Amneal Pharmaceuticals LLC2$45
Almatica Pharma LLC2$39
Abbott2$36
Lundbeck LLC1$27
Medtronic1$27
Acorda Therapeutics, Inc1$24
Idorsia Pharmaceuticals US Inc1$24
Sumitomo Pharma America, Inc.2$23
IBSA Pharma Inc.1$23
E.r. Squibb & Sons, L.L.C.1$20
Romark Laboratories, LC1$17
Avanir Pharmaceuticals, Inc.1$17
Lucid Diagnostics Inc.1$17
Azurity Pharmaceuticals, Inc.1$17
Biohaven Pharmaceuticals, Inc.1$17
Incyte Corporation1$17
Endo Pharmaceuticals Inc.1$16
Hikma Pharmaceuticals USA1$15
Novo Nordisk1$15
Adlon Therapeutics L.p.1$15
Axsome Therapeutics, Inc.1$14
Mission Pharmacal Company1$14
Mylan Specialty L.p.1$13
Nabriva Therapeutics, PLC1$12
Currax Pharmaceuticals LLC1$12

How this compares

$11,224 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$159,898
Medicare patients
230
Services billed
1,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$22,882
EliquisApixaban20$15,031
JanumetSitagliptin Phos/Metformin Hcl16$10,517
MyrbetriqMirabegron11$4,926
NamzaricMemantine Hcl/Donepezil Hcl11$3,691
SynthroidLevothyroxine Sodium21$2,082
Amlodipine Besylate168$1,745
Levothyroxine Sodium128$1,565
Atorvastatin Calcium136$1,392
Gabapentin64$1,325
Losartan Potassium107$1,323
Metoprolol Succinate74$1,167
ValacyclovirValacyclovir Hcl23$1,116
Methylprednisolone96$899
Escitalopram Oxalate32$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$22,88218 claims
PfizerEliquis$560$15,03120 claims
MerckJanumet$401$10,51716 claims
AbbVieNamzaric, Synthroid$3,676$5,77332 claims
Astellas Pharma US IncMyrbetriq$637$4,92611 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$45$1,565128 claims
Hikma Pharmaceuticals USAMorphine Sulfate$15$51613 claims
Almatica Pharma LLCSertraline Hcl$39$29720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →